BRPI0519013A2 - composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto - Google Patents

composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0519013A2
BRPI0519013A2 BRPI0519013-4A BRPI0519013A BRPI0519013A2 BR PI0519013 A2 BRPI0519013 A2 BR PI0519013A2 BR PI0519013 A BRPI0519013 A BR PI0519013A BR PI0519013 A2 BRPI0519013 A2 BR PI0519013A2
Authority
BR
Brazil
Prior art keywords
compound
stereoisomers
mixtures
salts
pharmaceutically acceptable
Prior art date
Application number
BRPI0519013-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel T W Chu
Jian Chen
Qiang Cong
Donald R James
Xianfeng Li
Jiangao Song
Bing Wang
Wei Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0519013A2 publication Critical patent/BRPI0519013A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
BRPI0519013-4A 2004-12-13 2005-12-09 composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto BRPI0519013A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US63558104P 2004-12-13 2004-12-13
US65670905P 2005-02-25 2005-02-25
US65671005P 2005-02-25 2005-02-25
US67538605P 2005-04-27 2005-04-27
US70258005P 2005-07-26 2005-07-26
PCT/US2005/044768 WO2006065686A2 (en) 2004-12-13 2005-12-09 Spiro derivatives as lipoxygenase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0519013A2 true BRPI0519013A2 (pt) 2009-11-03

Family

ID=36370831

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519013-4A BRPI0519013A2 (pt) 2004-12-13 2005-12-09 composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto

Country Status (8)

Country Link
US (1) US7576094B2 (enExample)
EP (1) EP1836183A2 (enExample)
JP (1) JP2008523145A (enExample)
AU (1) AU2005316739A1 (enExample)
BR (1) BRPI0519013A2 (enExample)
CA (1) CA2589363A1 (enExample)
MX (1) MX2007007103A (enExample)
WO (1) WO2006065686A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
AU2005328327A1 (en) * 2005-02-25 2006-09-08 Galileo Pharmaceuticals, Inc. Novel lipoxygenase inhibitors
US20080207588A1 (en) * 2005-02-25 2008-08-28 Chu Daniel T W Spiro-Heterocyclic Chromans, Thiochromans and Dihydroquinolines
BRPI0710507A2 (pt) * 2006-04-18 2011-08-16 Abbott Lab Antagonistas do receptor vanilóide de subtipo 1 (vr1) e usos destes
EP2097380A1 (en) * 2006-11-15 2009-09-09 High Point Pharmaceuticals, LLC New haloalkylsulfone substituted compounds useful for treating obesity and diabetes
CA2669867A1 (en) * 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes
EP2097388B1 (en) * 2006-11-15 2011-09-07 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
US8022066B2 (en) * 2006-11-15 2011-09-20 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
NZ595776A (en) * 2007-12-18 2013-08-30 Glenmark Pharmaceuticals Sa Chromane derivatives as trpv3 modulators
EP2229388A4 (en) 2008-01-11 2012-03-07 Glenmark Pharmaceuticals Sa CONDENSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS
UA104861C2 (uk) * 2008-06-17 2014-03-25 Гленмарк Фармас'Ютікалз С.А. Похідні хроману як модулятори trpv3
US8318928B2 (en) 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
CA2744911A1 (en) 2008-12-26 2010-07-01 Glenmark Pharmaceuticals, S.A. Fused imidazole derivatives as trpv3 antagonist
CA2924141C (en) 2013-08-22 2022-06-07 The General Hospital Corporation 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
SI3417851T1 (sl) 2013-09-09 2020-11-30 Peloton Therapeutics, Inc. Aril etri in njihova uporaba
WO2015095048A1 (en) * 2013-12-16 2015-06-25 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
JP2017502961A (ja) * 2013-12-23 2017-01-26 アレクトス セラピューティックス インコーポレイテッド グルコセレブロシダーゼモジュレーターおよびその使用
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
EP3268362B1 (en) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
KR20220155593A (ko) * 2020-03-19 2022-11-23 아르커스 바이오사이언시즈 인코포레이티드 Hif-2알파의 억제제로서의 테트랄린 및 테트라히드로퀴놀린 화합물
MX2024007932A (es) * 2021-12-23 2024-09-18 Univ Leuven Kath Spiros y analogos relacionados para inhibir yap/taz-tead.

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3331846A (en) 1963-08-28 1967-07-18 Lilly Co Eli Metal catalyst process for converting alpha-amino-acetylenes to dihydroquinoline
US3574627A (en) 1969-02-06 1971-04-13 Eastman Kodak Co Color photographic elements
JPS5265267A (en) 1975-11-26 1977-05-30 Takeda Chem Ind Ltd Synthesis of spiro compounds
JPS6030671B2 (ja) 1976-12-13 1985-07-17 武田薬品工業株式会社 スピロ化合物
US4284644A (en) 1977-01-12 1981-08-18 Takeda Chemical Industries, Ltd. Spirobenzofuranone compounds
US4342779A (en) 1977-12-27 1982-08-03 Takeda Chemical Industries, Ltd. 7-Acetylspirobenzofuranone compound
DK149891C (da) 1977-12-27 1987-06-15 Takeda Chemical Industries Ltd Analogifremgangsmaade til fremstilling af spirobenzofuranon-forbindelser eller salte deraf med uorganiske eller organiske syrer eller alkalimetaller
JPS5646879A (en) 1979-09-25 1981-04-28 Takeda Chem Ind Ltd Spiro compound, its preparation, and preventive and remedy for circulatory system disorder
US4330554A (en) 1980-04-23 1982-05-18 Takeda Chemical Industries, Ltd. Spirobenzofuranone compounds
FI79535C (fi) 1982-05-06 1990-01-10 Erba Farmitalia Foerfarande foer framstaellning av dihydrobensopyrans och dihydrobensotiopyrans substituerade iminoderivat.
EP0095316B1 (en) 1982-05-21 1986-12-03 Beecham Group Plc Pharmaceutically active aminobenzopyrans
EP0126311B1 (en) 1983-05-18 1989-09-13 Beecham Group Plc Benzopyran derivatives.
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
US4761403A (en) 1986-04-09 1988-08-02 Abbott Laboratories Lipoxygenase inhibiting compounds
DE3777656D1 (de) 1986-08-08 1992-04-23 Upjohn Co Mittel zur behandlung von alopezien.
GB8625185D0 (en) 1986-10-21 1986-11-26 Beecham Group Plc Active compounds
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5387587A (en) 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
DE3777366D1 (de) 1986-12-27 1992-04-16 Takeda Chemical Industries Ltd 2,3-dihydro-cumaron-derivate, ihre herstellung und verwendung.
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
GB8723157D0 (en) 1987-10-02 1987-11-04 Beecham Group Plc Compounds
US5059609A (en) 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
JPH07121936B2 (ja) 1988-03-28 1995-12-25 キッセイ薬品工業株式会社 ジヒドロベンゾフラノン誘導体
US5021432A (en) 1988-04-26 1991-06-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzopyran compound and its pharmaceutical use
AU628331B2 (en) 1988-05-06 1992-09-17 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US4950684A (en) 1988-05-20 1990-08-21 G. D. Searle & Co. 2,2-di-substituted benzopyran leukotriene-D4 antagonists
US5015661A (en) 1988-08-09 1991-05-14 Hoffmann-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
GB8902118D0 (en) 1989-02-01 1989-03-22 Beecham Group Plc Chemical process
US5232938A (en) 1989-05-24 1993-08-03 Beecham Group P.L.C. Certain 1,2,4-triazole(oxy or amino)benzopyran derivatives having pharmacological activity
DE3918041A1 (de) 1989-06-02 1990-12-06 Merck Patent Gmbh Chromanderivate
GB8915315D0 (en) 1989-07-04 1989-08-23 Sandoz Ltd Pharmaceutical compositions for use against hypertension and congestive heart failure
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
JPH0366669A (ja) 1989-08-03 1991-03-22 Shionogi & Co Ltd 複素環式化合物
GB8924373D0 (en) 1989-10-30 1989-12-20 Beecham Group Plc Novel compounds
GB8928837D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Pharmaceuticals
GB2242628A (en) 1990-04-06 1991-10-09 Sandoz Ltd Asthma prophylactic use of K+ channel activators
WO1991016888A1 (en) 1990-04-23 1991-11-14 Rhone-Poulenc Rorer International (Holdings), Inc. Spiro[benzofurancycloalkane]carboxamides as 5ht3 antagonists
BE1004295A3 (fr) 1990-05-17 1992-10-27 Sandoz Sa Utilisation des activateurs des canaux potassiques pour la prophylaxie de l'asthme.
US5076835A (en) 1990-05-31 1991-12-31 America Cyanamid Company Aryloxyspiroalkylindolinone herbicides
DE4018552A1 (de) 1990-06-09 1991-12-12 Sandoz Ag Asthma-prophylaktische verwendung von k(pfeil hoch)+(pfeil hoch) kanal-activatoren
ES2030627A6 (es) 1990-11-28 1992-11-01 Uriach & Cia Sa J Procedimiento para la obtencion de compuestos benzopiranicos.
JP2612971B2 (ja) 1991-02-19 1997-05-21 吉富製薬株式会社 ベンゾピラン化合物
DE4115521A1 (de) 1991-05-11 1992-11-12 Beiersdorf Ag Isoindolyl- und isochinolylsubstituierte benzopyran-derivate, zwischenprodukte, sowie verfahren zu ihrer herstellung
US5624954A (en) 1991-06-13 1997-04-29 Smithkline Beecham P.L.C. Benzo- and pyridopyran derivatives having anxiolytic and anti-convulsant activity
GB9112721D0 (en) 1991-06-13 1991-07-31 Smithkline Beecham Plc Novel treatment
US5250547A (en) 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
CA2053962A1 (en) 1991-10-22 1993-04-23 Theo Schotten Benzopyran derivatives, process for their preparation and use thereof and preparations containing the compounds
CA2124086A1 (en) 1991-11-22 1993-05-27 Ronald H. Lane Tocotrienols and tocotrienol-like compounds and methods for their use
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5686624A (en) 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
AU661159B2 (en) 1992-07-15 1995-07-13 Sumitomo Chemical Company, Limited N-acyldihydroquinoline derivatives, a method for producing the same and their use as herbicides
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1994007867A1 (en) 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
US5939346A (en) 1992-11-02 1999-08-17 Akzo Nobel N.V. Catalyst system comprising an aryloxyaluminoxane containing an electron withdrawing group
FI952609L (fi) 1992-11-30 1995-05-30 Smithkline Beecham Plc Bentsopyronianalogit ahdistuksen, manian, masennuksen tai vieroitusoireiden hoitamiseksi
KR100305149B1 (ko) 1992-12-11 2001-11-22 피터 기딩스 이환식화합물을함유한제약조성물
GB9225859D0 (en) 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
NZ258610A (en) 1992-12-11 1997-05-26 Smithkline Beecham Plc Various 4-acylamino-2h-benzo[b]pyran-3-ol derivatives;use in preparation of medicaments
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
JPH07188210A (ja) 1993-11-19 1995-07-25 Chugai Pharmaceut Co Ltd ベンゾピラン−４−カルボン酸誘導体の製造法
US5399562A (en) 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
TW279878B (enExample) 1994-03-18 1996-07-01 Sumitomo Chemical Co
JP3528242B2 (ja) 1994-06-23 2004-05-17 住友化学工業株式会社 ヒドロキシフラバン化合物の製造方法
DE4428932A1 (de) 1994-08-16 1996-02-22 Hoechst Ag Substituierte-Chinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
KR960010744A (ko) 1994-09-07 1996-04-20 고사이 아키오 고무 조성물 및 이를 사용하는 가황 접착방법
WO1996011920A1 (en) 1994-10-13 1996-04-25 Pfizer Inc. Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4 (ltb4) antagonists
JP3012339B2 (ja) 1994-10-13 2000-02-21 ファイザー・インコーポレーテッド ベンゾピランおよびベンゾ縮合化合物、それらの製造、並びにロイコトリエンｂ▲下４▼（ｌｔｂ▲下４▼）アンタゴニストとしてのそれらの用途
US5693646A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5925673A (en) 1994-12-23 1999-07-20 Alcon Laboratories, Inc. Benzofurans and benzopyrans as cytoprotective agents
US5674876A (en) 1995-01-20 1997-10-07 Research Development Foundation ρ-heteroatom-substituted phenols and uses thereof
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
US5606006A (en) 1996-04-08 1997-02-25 Shell Oil Company Trisepoxy resin compositions
AU4136897A (en) 1996-09-09 1998-03-26 Dainippon Pharmaceutical Co. Ltd. 2,3-dihydrobenzofuran derivative and hepatopathy remedy comprising the same as active ingredient
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
US6005007A (en) 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
EP1068193A1 (en) 1998-02-26 2001-01-17 Neurogen Corporation Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d 4? receptor antagonists
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19854147A1 (de) 1998-11-24 2000-05-25 Basf Ag Verwendung von N-substituierten Azabicycloalkan-Derivaten zur Verwendung bei der Bekämpfung der Cocainsucht
FR2787451B1 (fr) 1998-12-18 2001-01-26 Adir Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2787789B1 (fr) 1998-12-29 2002-06-14 Lipha Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
US20030212109A1 (en) 2000-06-02 2003-11-13 Mitchell Stephen Nicholas Pharmaceutical compositions and their use
CA2417156A1 (en) 2000-08-01 2003-01-23 Ono Pharmaceutical Co., Ltd. 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient
US6369225B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
ES2256288T3 (es) 2000-08-29 2006-07-16 Allergan, Inc. Compuestos con actividad como inhibidores de citocromo p450rai.
US6252090B1 (en) 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6291677B1 (en) 2000-08-29 2001-09-18 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
GB0028697D0 (en) 2000-11-23 2001-01-10 S P A Novel process
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
AU2003286604A1 (en) 2002-10-21 2004-05-13 Irm Llc Oxindoles with anti-hiv activity
DE10335450A1 (de) 2003-08-02 2005-02-17 Bayer Ag Indolin-Sulfanilsäureamide
DE10335449A1 (de) 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
US7470798B2 (en) 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
JP2007516298A (ja) 2003-12-23 2007-06-21 アリーナ ファーマシューティカルズ， インコーポレイテッド 新規なスピロインドリンまたはスピロイソキノリン化合物、それらの使用方法および組成物
AU2005205016B2 (en) 2004-01-16 2010-07-15 F. Hoffmann-La Roche Ag 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1H-quinazolin-2-one derivatives and the respective 1H-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(D) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-HT) for the treatment of diseases of the central nervous system
EP1589015A1 (en) 2004-02-03 2005-10-26 Université de Liège Benzopyran derivatives, method of production and use thereof
US20060106014A1 (en) 2004-10-14 2006-05-18 Sekhar Boddupalli Methods for treating diabetes
US20080207588A1 (en) 2005-02-25 2008-08-28 Chu Daniel T W Spiro-Heterocyclic Chromans, Thiochromans and Dihydroquinolines
AU2005328327A1 (en) 2005-02-25 2006-09-08 Galileo Pharmaceuticals, Inc. Novel lipoxygenase inhibitors

Also Published As

Publication number Publication date
CA2589363A1 (en) 2006-06-22
MX2007007103A (es) 2008-03-10
WO2006065686A3 (en) 2006-08-24
EP1836183A2 (en) 2007-09-26
US20060128790A1 (en) 2006-06-15
WO2006065686A2 (en) 2006-06-22
JP2008523145A (ja) 2008-07-03
AU2005316739A1 (en) 2006-06-22
US7576094B2 (en) 2009-08-18

Similar Documents

Publication Publication Date Title
BRPI0519013A2 (pt) composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
BRPI0513717A (pt) derivados de piridina
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
BRPI0908353B8 (pt) composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica
TW200716596A (en) Substituted amide derivatives and methods of use
PA8777901A1 (es) "derivados de quinolina -carboxamida en calidad de antagonistas de p2y12"
MX2007010072A (es) Derivados de piperidina antibacterianos.
TW200806300A (en) New therapeutic combinations for the treatment of depression
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
CR9954A (es) Derivados de pirazina
BRPI0519979A2 (pt) composto ou estereoisÈmeros, misturas de estereoisÈmeros ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, e, uso de um composto
BR0314299A (pt) Derivados de pirrolidona como inibidores de mao-b
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200626158A (en) Naphthaline derivatives
EA200971017A1 (ru) Аминоалкоксиарилсульфонамидные соединения и их применение в качестве 5-нтлигандов

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ESCLARECO O DEPOSITANTE A OMISSAO DO NOME DO INVENTOR CONG, GIANG NO DOCUMENTO DE CESSAO APRESENTADO ATRAVES DA PETICAO NO 020070112613 DE 13/08/2007, CONSTANTE DA PUBLICACAO INTERNACIONAL - WO, E A OMISSAO DO NOME DO INVENTOR ARKADIJ ELIZAROV DA PUBLICACAO INTERNACIONAL - WO E CONSTANTE DO DOCUMENTO DE CESSAO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.